

Clinical Trial Protocol

Iranian Registry of Clinical Trials

09 Jul 2026

A comparative study of the effects of Tocilizumab, interferon-gamma and vitamin C on the recovery of critically ill Covid-19 patients and cytokine storm

Protocol summary

Study aim

Effects of Tocilizumab, interferon-gamma and vitamin C on serum ferritin, LDH, CPK, CRP lung tissue, heart, lymphocytes, neutrophils, PCO₂, and serological tests.

Design

The randomized clinical trial consists of a control group, two parallel groups, non blinded, and phase 2. All the 60 patients are systematically assigned to random groups. Randomization will be conducted by SAS software.

Settings and conduct

This clinical trial will be undertaken at Ahar Hospital, in East Azarbaijan Province, Iran, under the supervision of Tabriz University of Medical Sciences. It is approved by the ethics committee of TUOMS. In all patients, the serum levels of ferritin, LDH, CPK, CRP, IL1, IL6, IL18, TNF α should be significantly higher, and pulmonary involvement should be evident in the CT scan. In addition to the routine medication, Group 1 will receive the Tocilizumab Vial. Group 2 will receive interferon-gamma and Vitamin C besides the usual medication, and the control group will receive only the routine medication. All patients will be monitored for two weeks. In the first and last days of treatment, a CT scan will be performed for patients to examine the lungs and heart. Blood samples will also be taken to check blood constituents (neutrophils, lymphocytes, ferritin, ALT, AST, VBG). In the next step, PCO₂ will be measured. All of the above steps will be repeated on days 3-7-10, and 14.

Participants/Inclusion and exclusion criteria

Inclusion criteria: Lack of a specific clinical disease, 18 to 65 years of age, no pregnancy, symptoms of cytokine storm, Exclusion criteria: An underlying illness, under 18 and over 65 years of age, pregnancy

Intervention groups

1: Tocilizumab along with routine medications, 2: interferon-gamma and Injectable vitamin C along with

routine medications, 3: Only routine medications

Main outcome variables

Ferritin serum LDH CPK CRP IL1, IL6, IL18, TNF α

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20200525047570N1**

Registration date: **2020-07-30, 1399/05/09**

Registration timing: **prospective**

Last update: **2020-07-30, 1399/05/09**

Update count: **0**

Registration date

2020-07-30, 1399/05/09

Registrant information

Name

Negin Hadisi

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 44 4432 6311

Email address

nhadisi72@yahoo.com

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2020-07-31, 1399/05/10

Expected recruitment end date

2020-08-07, 1399/05/17

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

A comparative study of the effects of Tocilizumab, interferon-gamma and vitamin C on the recovery of critically ill Covid-19 patients and cytokine storm

Public title

A comparative study of the effects of Tocilizumab, interferon-gamma and vitamin C on the recovery of critically ill Covid-19 patients and cytokine storm

Purpose

Treatment

Inclusion/Exclusion criteria**Inclusion criteria:**

Lack of a specific clinical disease
Non-use of a particular drug
No pregnancy

Exclusion criteria:

A specific clinical disease
Taking a particular drug
Pregnancy

Age

From **18 years** old to **65 years** old

Gender

Both

Phase

2

Groups that have been masked

No information

Sample size

Target sample size: **60**

Randomization (investigator's opinion)

Randomized

Randomization description

Considering the budget allocated by Tabriz University of Medical Sciences and the relatively low number of acute patients in Baqer al-Olum Hospital in Ahar, we will use the "simple randomization method, the ratio of 1:1, in this study, and the SAS statistical software is utilized as the randomization tool.

Blinding (investigator's opinion)

Not blinded

Blinding description**Placebo**

Not used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Ethics Committee in Research, Tabriz University of

Medical Sciences

Street address

Jangdoost Alley, Vahdat Street, Next to the Pouri Post Bank, Naser Hadisi

City

Sardasht

Province

West Azarbaijan

Postal code

5961658164

Approval date

2020-05-18, 1399/02/29

Ethics committee reference number

IR.TBZMED.REC.1399.130

Health conditions studied**1****Description of health condition studied**

Covid-19

ICD-10 code

U07.1

ICD-10 code description

Covid-19 disease

Primary outcomes**1****Description**

Blood ferritin levels

Timepoint

Days 1-3-7-10-14

Method of measurement

ELISA kit

2**Description**

Blood C-reactive protein levels

Timepoint

Days 1-3-7-10-14

Method of measurement

ELISA kit

3**Description**

Blood creatine Phosphokinase levels

Timepoint

Days 1-3-7-10-14

Method of measurement

ELISA kit

4**Description**

Low-density lipoprotein levels

Timepoint

Days 1-3-7-10-14

Method of measurement

ELISA kit

5

Description

Lung tissue

Timepoint

Days 1 and 14

Method of measurement

Computed tomography CT-scan

6

Description

Blood Lymphocyte levels

Timepoint

Days 1-3-7-10-14

Method of measurement

ELISA kit

7

Description

Blood Neutrophil levels

Timepoint

Days 1-3-7-10-14

Method of measurement

ELISA kit

8

Description

Partial pressure of carbon dioxide (PCO2)

Timepoint

Days 1-3-7-10-14

Method of measurement

Arterial blood gas test

Secondary outcomes

1

Description

Tumor necrosis factor alpha, TNFa

Timepoint

Days 1, 3, 7, 14

Method of measurement

ELISA Kit

2

Description

Interleukin 1

Timepoint

Days 1, 3, 7, 14

Method of measurement

ELISA Kit

3

Description

Interleukin 6

Timepoint

Days 1, 3, 7, 14

Method of measurement

ELISA Kit

4

Description

Interleukin 18

Timepoint

Days 1, 3, 7, 14

Method of measurement

ELISA Kit

Intervention groups

1

Description

Intervention Group 1 receives Tocilizumab Vial, a humanized antibody, and an interleukin 6 receptor. A dose of 162mg/0.9ml will be administered once a week Subconsciously for two weeks. Currently, no specific manufacturer has been chosen yet.

Category

Treatment - Drugs

2

Description

Intervention Group 2 receives Interferon gamma Vial, a humanized antibody, and an interleukin 12 receptor. A dose of 5mg/200mcg, subcutaneous, every alter day, and Vitamin C a dose of 500mg every 8h will be administered for one week. Currently, no specific manufacturer has been chosen yet.

Category

Treatment - Drugs

3

Description

Control group: : Only routine medications

Category

Diagnosis

Recruitment centers

1

Recruitment center

Name of recruitment center

Bagher-Al-Olum Hospital of Ahar

Full name of responsible person

Negin Hadisi

Street address

Vahdat Street., Jangdoost Alley., Next to the Pouri Post Bank., Naser Hadisi

City

Sardasht

Province

West Azarbaijan

Postal code

5961658164

Phone

+98 44 4432 6311

Email

nhadisi72@yahoo.com

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Tabriz University of Medical Sciences

Full name of responsible person

Mohammad Hossein Somi

Street address

Vahdat Street,. Jangdoost Alley,. Next to the Pouri
Post Bank,. Naser Hadisi

City

Sardasht

Province

West Azarbaijan

Postal code

5961658164

Phone

+98 44 4432 6311

Email

nhadisi72@yahoo.com

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Tabriz University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Tabriz University of Medical Sciences

Full name of responsible person

Negin Hadisi

Position

Student of the last term of Master of Anatomical
Sciences

Latest degree

Master

Other areas of specialty/work

Midwife of women ward

Street address

Vahdat Street,. Jangdoost Alley,. Next to the Pouri
Post Bank,. Naser Hadisi

City

Sardasht

Province

West Azarbaijan

Postal code

5961658164

Phone

+98 44 4432 6311

Email

nhadisi72@yahoo.com

Person responsible for scientific inquiries

Contact

Name of organization / entity

Tabriz University of Medical Sciences

Full name of responsible person

Negin Hadisi

Position

Student of Master of Anatomical Sciences

Latest degree

Master

Other areas of specialty/work

Anatomy

Street address

Vahdat Street,. Jangdoost Alley,. Next to the Pouri
Post Bank,. Naser Hadisi

City

Sardasht

Province

West Azarbaijan

Postal code

5961658164

Phone

+98 44 4432 6311

Email

nhadisi72@yahoo.com

Person responsible for updating data

Contact

Name of organization / entity

Tabriz University of Medical Sciences

Full name of responsible person

Negin Hadisi

Position

Student of Master of Anatomical Sciences

Latest degree

Master

Other areas of specialty/work

Anatomy

Street address

Vahdat Street,. Jangdoost Alley,. Next to the Pouri
Post Bank,. Naser Hadisi

City

Sardasht

Province

West Azarbaijan

Postal code

5961658164

Phone

004444326311

Email

nhadisi72@yahoo.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Yes - There is a plan to make this available

Study Protocol

Yes - There is a plan to make this available

Statistical Analysis Plan

Yes - There is a plan to make this available

Informed Consent Form

Yes - There is a plan to make this available

Clinical Study Report

Yes - There is a plan to make this available

Analytic Code

Not applicable

Data Dictionary

Not applicable

Title and more details about the data/document

All the objectives and consequences of (All the data related) the participants' documents can be shared anonymously.

When the data will become available and for how long

The obtained data can be immediately accessed after samples are collected in the summer of 2020.

To whom data/document is available

Data and other documents can be sent to individuals working in academic and scientific institutions.

Under which criteria data/document could be used

Data can only be sent to individuals working in academic and scientific institutions, as well as physicians in the field of treatment.

From where data/document is obtainable

For more information , you can reach Negin Hadisi. Please send your request by a verified email to the following address: nhadisi72@yahoo.com

What processes are involved for a request to access data/document

Please send your request by a verified email

Comments